StockData
AstraZeneca PLC logo

AstraZeneca PLC

AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)

Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%

AstraZeneca Enhertu (trastuzumab deruxtecan by Quarter

Enhertu (trastuzumab deruxtecan — direct product sales) — Worldwide product sales ($M) ($M)

QuarterlyAnnual

AstraZeneca Enhertu (trastuzumab deruxtecan: $338M in Q2 2026, up 47.0% from a year earlier. That is the highest of the 22 quarters on record here.

Latest, Q2 2026
338
Period ended Jun 30, 2026
Change on a year earlier
+47.0%
230 in Q2 2025
History
22 quarters
Since Q1 2021
Sources
22
Documents cited below

Where the Q2 2026 figure comes from

“|| Enhertu | | 338 | | 47 | | 44 | | - | | - | | 223 | | 43 | | 41 | | 68 | | 34 | | 28 | | 47 | | n/m | | 98”

Source: Form 6-K FY2026Q2 Earnings Release ↗

Reported in Form 6-K Quarterly & Form 20-F Product Sales by Medicine & Region Tables.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedEnhertu (trastuzumab deruxtecan — direct product sales) — Worldwide product sales ($M) ($M)Year on yearSource
Q2 2026Jun 30, 2026338+47.0%Form 6-K FY2026Q2 Earnings Release ↗
Q1 2026Mar 31, 2026324+63.6%Form 6-K FY2026Q1 Earnings Release ↗
Q4 2025Dec 31, 2025292+97.3%Form 6-K FY2025Q4 Earnings Release ↗
Q3 2025Sep 30, 2025257+73.6%Form 6-K FY2025Q3 Earnings Release ↗
Q2 2025Jun 30, 2025230+81.1%Form 6-K FY2025Q2 Earnings Release ↗
Q1 2025Mar 31, 2025198+62.3%Form 6-K FY2025Q1 Earnings Release ↗
Q4 2024Dec 31, 2024148+78.3%Form 6-K FY2024Q4 Earnings Release ↗
Q3 2024Sep 30, 2024148+102.7%Form 6-K FY2024Q3 Earnings Release ↗
Q2 2024Jun 30, 2024127+89.6%Form 6-K FY2024Q2 Earnings Release ↗
Q1 2024Mar 31, 2024122+229.7%Form 6-K FY2024Q1 Earnings Release ↗
Q4 2023Dec 31, 202383+196.4%Form 6-K FY2023Q4 Earnings Release ↗
Q3 2023Sep 30, 202373+217.4%Form 6-K FY2023Q3 Earnings Release ↗
Q2 2023Jun 30, 202367+272.2%Form 6-K FY2023Q2 Earnings Release ↗
Q1 2023Mar 31, 202337+236.4%Form 6-K FY2023Q1 Earnings Release ↗
Q4 2022Dec 31, 202228+300.0%Form 6-K FY2022Q4 Earnings Release ↗
Q3 2022Sep 30, 202223+360.0%Form 6-K FY2022Q3 Earnings Release ↗

Breakdown

What makes up enhertu (trastuzumab deruxtecan

Cite this data

StockData. (2026). AstraZeneca Enhertu (trastuzumab deruxtecan ($M), quarterly Q1 2021–Q2 2026 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/med-enhertu-world

See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.